COVID-19, RWE, and more on the April issue of GPU

The April issue of the Government & Policy Update dedicates ample room to the impact of COVID-19 on the management of clinical trials. Among the other principal topics, the latest monthly GPU deals with:

  • Real-World Evidence
  • EU/Brexit
  • Clinical Trials
  • Clinical Trial Disclosure
  • Drug Development
  • Gene Therapy
  • Pricing
  • Drug Quality
  • Drug Safety
  • Drug Shortages.

Further information concern the most relevant decisions from EMA, FDA, and other regulatory authorities.

Maxer Consulting (Italy), in collaboration with Paarlberg and Associates (US), monthly edits the GPU to provide pharma companies and CROs with an executive summary that encompasses the most relevant updates of the ever-changing international pharmaceutical landscape. Drug development, regulatory affairs, clinical trial disclosure, medical marketing, health technology assessment, pharmacovigilance, and other critical topics have specific attention in GPU.